Drug Trial Radar · NCT01628913
Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
Last checked: Nov 19, 2026Latest source record: Apr 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
62
Actual
Start
Oct 2012
Primary completion
Sep 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter, open label, randomized phase II study to evaluate the efficacy and safety of BEZ235 as compared to everolimus in patients with advanced, low to intermediate grade pancreatic neuroendocrine tumor (pNET).
Conditions
- Pancreatic Neuroendocrine Tumors (pNET)
Interventions
BEZ235Drug
BEZ235 400 mg bid p.o. (by mouth, twice daily)
EverolimusDrug
Everolimus 10 mg qd p.o. (by mouth, daily)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: up to approx. 18 months
Locations
26 sites in 8 countries. Site status is shown where the registry gives one.
Cedars Sinai Medical Center SC-3
Los Angeles, California
University of Colorado Univ Colorado
Aurora, Colorado
University of Kentucky Univ Kebtucky
Lexington, Kentucky
Montefiore Medical Center SC
The Bronx, New York
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Reims, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Pisa, PI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Groningen, Netherlands
Novartis Investigative Site
Kazan', Russia
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Catalonia, Spain
Novartis Investigative Site
Madrid, Madrid, Spain
Novartis Investigative Site
Madrid, Madrid, Spain
Novartis Investigative Site
Lucerne, Switzerland
Novartis Investigative Site
Glasgow, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Manchester, United Kingdom
Novartis Investigative Site
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.